Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    22563089 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Phase II Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
Condition: Leukemia, Mast-Cell
Interventions: Procedure: nonmyeloablative allogeneic hematopoietic cell transplant;   Drug: Cixutumumab;   Drug: Paclitaxel

Indicates status has not been verified in more than two years